Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy

Jasmine Rana; Nolan J Maloney; Kerri E Rieger; Silvina B Pugliese; Jenna L Strelo; Anne Liu; Lisa C Zaba; Bernice Y Kwong

doi:10.1016/j.jdcr.2021.04.033

Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy

JAAD Case Rep. 2021 May 13:13:147-151. doi: 10.1016/j.jdcr.2021.04.033. eCollection 2021 Jul.

Authors

Jasmine Rana¹, Nolan J Maloney², Kerri E Rieger¹, Silvina B Pugliese¹, Jenna L Strelo¹, Anne Liu¹, Lisa C Zaba¹, Bernice Y Kwong¹

Affiliations

¹ Department of Dermatology, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
² Division of Dermatology, Department of Medicine, David Geffen School of Medicine, The University of California, Los Angeles, California.

No abstract available

Keywords: BRAF; BRAF inhibitor; BRAFi, BRAF inhibitors; CTLA4; DIHS; DIHS, drug-induced hypersensitivity syndrome; DLR, DIHS-like reaction; DRESS; ICI; ICI, immune checkpoint inhibitor; PD-1; PD-L1; PD1; TT, targeted therapy; dabrafenib; encorafenib; immune checkpoint therapy; immune related adverse effect; irAE; ircAE; oncoderm; rash; vemurafenib.

Publication types

Case Reports